These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 24111645

  • 1. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
    Baş M, Greve J, Hoffmann TK, Reshef A, Aberer W, Maurer M, Kivity S, Farkas H, Floccard B, Arcoleo F, Martin L, Sitkauskiene B, Bouillet L, Schmid-Grendelmeier P, Li H, Zanichelli A.
    Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
    [Abstract] [Full Text] [Related]

  • 2. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
    Lumry WR, Farkas H, Moldovan D, Toubi E, Baptista J, Craig T, Riedl M.
    Int Arch Allergy Immunol; 2015 Nov; 168(1):44-55. PubMed ID: 26556097
    [Abstract] [Full Text] [Related]

  • 3. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
    Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, Riedl M, Li H, Craig T, Bloom BJ, Reshef A.
    Ann Allergy Asthma Immunol; 2011 Dec; 107(6):529-37. PubMed ID: 22123383
    [Abstract] [Full Text] [Related]

  • 4. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.
    Malbrán A, Riedl M, Ritchie B, Smith WB, Yang W, Banerji A, Hébert J, Gleich GJ, Hurewitz D, Jacobson KW, Bernstein JA, Khan DA, Kirkpatrick CH, Resnick D, Li H, Fernández Romero DS, Lumry W.
    Clin Exp Immunol; 2014 Aug; 177(2):544-53. PubMed ID: 24749847
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
    Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anné S, Björkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hébert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernández Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT.
    N Engl J Med; 2010 Aug 05; 363(6):532-41. PubMed ID: 20818888
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Icatibant for the treatment of hereditary angioedema.
    Cole SW, Lundquist LM.
    Ann Pharmacother; 2013 Jan 05; 47(1):49-55. PubMed ID: 23249729
    [Abstract] [Full Text] [Related]

  • 12. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
    Otani IM, Lumry WR, Hurwitz S, Li HH, Craig TJ, Holtzman NS, Iandoli MI, Tucker J, Riedl MA, Zuraw BL, Banerji A.
    J Allergy Clin Immunol Pract; 2017 Jan 05; 5(2):442-447.e1. PubMed ID: 27818136
    [Abstract] [Full Text] [Related]

  • 13. [EFFICACY, PHARMACOKINETICS, AND SAFETY OF ICATIBANT FOR THE TREATMENT OF JAPANESE PATIENTS WITH AN ACUTE ATTACK OF HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Hide M, Fukunaga A, Maehara J, Eto K, Hao J, Vardi M, Nomoto Y.
    Arerugi; 2018 Jan 05; 67(2):139-147. PubMed ID: 29553114
    [Abstract] [Full Text] [Related]

  • 14. Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey.
    Longhurst HJ, Aberer W, Bouillet L, Caballero T, Fabien V, Zanichelli A, Maurer M, IOS Investigators.
    Allergy Asthma Proc; 2015 Jan 05; 36(5):399-406. PubMed ID: 26314822
    [Abstract] [Full Text] [Related]

  • 15. Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals.
    Hernández Fernandez de Rojas D, Ibañez E, Longhurst H, Maurer M, Fabien V, Aberer W, Bouillet L, Zanichelli A, Caballero T, IOS Study Group.
    Int Arch Allergy Immunol; 2015 Jan 05; 167(1):21-8. PubMed ID: 26112099
    [Abstract] [Full Text] [Related]

  • 16. Icatibant for hereditary angioedema.
    Gras J.
    Drugs Today (Barc); 2009 Dec 05; 45(12):855-64. PubMed ID: 20135020
    [Abstract] [Full Text] [Related]

  • 17. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
    Bouillet L, Boccon-Gibod I, Launay D, Gompel A, Kanny G, Fabien V, Fain O, IOS Study Group.
    Immun Inflamm Dis; 2017 Mar 05; 5(1):29-36. PubMed ID: 28250922
    [Abstract] [Full Text] [Related]

  • 18. Icatibant as acute treatment for hereditary angioedema in adults.
    Farkas H.
    Expert Rev Clin Pharmacol; 2016 Jun 05; 9(6):779-88. PubMed ID: 27123689
    [Abstract] [Full Text] [Related]

  • 19. Icatibant.
    Deeks ED.
    Drugs; 2010 Jun 05; 70(1):73-81. PubMed ID: 20030426
    [Abstract] [Full Text] [Related]

  • 20. Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial.
    Baş M.
    Expert Rev Clin Immunol; 2012 Nov 05; 8(8):707-17. PubMed ID: 23167682
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.